RM-GHA / Growth-hormone-axis signalling
CJC-1295 DAC
Also known as: CJC-1295 with DAC · Long-acting CJC-1295 · DAC:GRF
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
CJC-1295 DAC carries a reactive drug-affinity-complex modification designed to bind serum albumin. That modification is part of the tested molecule, not a packaging detail.
Evidence position
Direct controlled human pharmacology supports Grade B. The studies measured hormone exposure and secretion patterns; they did not establish an approved use or a broad clinical outcome.
What the record does not establish
The DAC studies cannot be attached to Mod GRF 1-29 or a product labelled “CJC-1295 no DAC.” None of the publications verifies the identity, purity, strength or microbiological quality of a supplier lot.
Sources
- 01Prolonged GH and IGF-I stimulation by CJC-1295 in healthy adultsPubMed
- Shows
- Randomised ascending-dose human pharmacology for the long-acting CJC-1295 form
- Does not show
- Healthy-adult biomarker study; not a clinical-outcome trial or evidence about a commercial sample
- 02Pulsatile GH secretion during continuous CJC-1295 stimulationPubMed
- Shows
- Human endocrine pharmacology for albumin-binding CJC-1295
- Does not show
- Small mechanistic study; does not apply to the no-DAC form
- 03Detection of GHRH synthetic analogsPubMed
- Shows
- Analytical work distinguishing CJC-1295 forms and metabolites
- Does not show
- Detection study, not an efficacy or lot-quality study
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Cjc 1295
- CID
- 91971820
- Formula
- C165H269N47O46
- Mass
- 3647.2
PUBMED / FOUND RECORDS
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism / 2006 MarPMID 16352683 / DOI 10.1210/jc.2005-1536
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews / 2026 Jan 1PMID 41490200 / DOI 10.5435/JAAOSGlobal-D-25-00236
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.The American journal of sports medicine / 2026 JanPMID 41476424 / DOI 10.1177/03635465251357593
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports medicine (Auckland, N.Z.) / 2026 Apr 12PMID 41966639 / DOI 10.1007/s40279-026-02437-0
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse / 2016 Jan 2PMID 26771670 / DOI 10.3109/10826084.2015.1082595